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Abstract: Through exomic sequencing of 10 hepatitis C virus (HCV)-
associated hepatocellular carcinomas (HCC) and subsequent evalua-
tion of additional affected individuals, we discovered novel inactivat-
ing mutations of ARID2 in four major subtypes of HCC (HCV-
associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-
associated HCC and HCC with no known etiology). Notably, 18.2%
of individuals with HCV-associated HCC in the United States and Eur-
ope harbored ARID2 inactivation mutations, suggesting that ARID2 is
a tumor suppressor gene that is relatively commonly mutated in this
tumor subtype.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver.Cancer is thought to develop from certain genetic and epigenetic
alterations that constitute 10 established and emerging hall-
marks that enable tumor initiation and progression through
tumor suppressor inactivation and oncogene activation [1].
Recently, advances in DNA sequencing technology, particularly
next generation sequencing (NGS), have provided an outlet for
a detailed and global perspective on the driving alterations in
cancer through high resolution analysis of tumor genomes [2,3].
Over the last few years, NGS has allowed for detailed analysisJournal of Hepatology 20
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atitis C virus; NGS, next generation sequencing.of DNA structural changes, chromosomal translocations, duplica-
tions and deletions in cancer driver or susceptibility genes in over
16 tumor types [4]. Over one-third of these studies rely on
sequencing select regions of the genome, such as the exome, to
reduce sequencing time as well as cost and to focus on relevant
protein-coding regions. While the beneﬁts of NGS technologies
include increased throughput and ever-reducing cost, several
challenges remain in translating sequencing information to clin-
ical practice.
NGS studies utilize various methods to deﬁne true mutations,
since a systematic general strategy to adequately mine this mas-
sive volume of data is not in place. For example, among the three
published NGS studies for hepatocellular carcinoma (HCC), a
lethal form of liver cancer that impacts global health, the authors
use different methods to capture exons, various bioinformatic
tools or algorithms to align sequences to reference genomes
and diverse criteria for selecting mutations based on coverage,
reads and frequency [5–7]. Thus, the mutations that pass these
selection criteria differ between studies. Moreover, mutation call-
ing by NGS is simply not perfect, with false positives generated
from machine errors or through the difﬁculty in differentiating
somatic mutations from more frequently occurring germline
inherited single nucleotide polymorphisms. Since the somatic
mutation rate per gene per cell is approximately 107, the prob-
ability of single or multiple mutations occurring within one cell is
highly unlikely within its lifespan [8]. Thus, identiﬁcation of true
mutations requires improved understanding of cancer biology
coupled with enhanced bioinformatics and validation using tradi-
tional Sanger DNA sequencing methods.
Tumor heterogeneity also inﬂuences the value of NGS data.
Distinguishing whether multiple mutation events occur within
each tumor cell (clonal evolution) vs. compilations of mutation
events contributed by different cells within a tumor remains a
challenge. NGS may play a signiﬁcant role in deﬁning such
intra-heterogeneous and inter-heterogeneous tumor types. In
order to begin distinguishing these differences, one must more
closely deﬁne the samples to be analyzed. Of the three published
HCC-related NGS studies, two have only examined a single indi-
vidual for mutation calling and failed to conﬁrm these putative
mutants in additional samples [5,6]. Hence, the importance of
these mutations is not clear in the context of the general HCC
population due to the lack of multiple discovery and validation
samples.
In their recent work, Li et al., have conducted an elegant study
to address this issue through an exomic sequencing screen of ten12 vol. 56 j 1412–1414
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Fig. 1. Next-generation sequencing (NGS) study design. The schematic shows ever-improving design of NGS-based studies to identify true driver mutations. Study design
A involves a single subject where NGS was used to identify a mutation of interest. Study design B improves on Study design A via validation, e.g. by Sanger sequencing, of
the mutation of interest within the same subject sample(s). Study design C utilizes a heterogeneous population of multiple individuals where a mutation of interest is
validated. Study design D is better and recommended, since it is focused on a homogeneous test population, with validation among the samples used in the initial study, as
well as validation in a separate cohort along with follow-up analysis to understand the functional consequence of the mutation.
JOURNAL OF HEPATOLOGYhepatitis C virus (HCV) positive HCC patients, followed by valida-
tion in 129 patients [7]. The authors found novel inactivating
ARID2mutations in HCC and infer that ARID2 is a HCC tumor sup-
pressor, since 18.2% of discovery samples harbored inactivating
mutations of this gene. Chromatograms of ARID2 mutations in
additional cases however, show a heterozygous nature which
may result from intra-tumor heterogeneity or normal cell con-
tamination, whose origination and interpretation require further
exploration. An examination of the contribution of CAMSAP1L and
EPS8L1mutants would be germane since these genes also met the
authors’ stringent criteria for calling tumor mutations. Further-
more, the DMXL1 and NLRP1 mutations found in the discovery
cases did not validate in the 23 additional HCV–HCC cases and
thus, may not be global driving mutations for this etiological sub-
set of HCC, which reinforces the necessity of data validation and
cohort design in NGS studies. By constructing a study to consider
mutations consistently occurring in several individuals frommul-
tiple centers, the authors provide noteworthy data on common
mutations that impact a disease on a macro level, rather than
mutants that exist in a single individual, which may have more
nominal effects. We congratulate the authors on effectively man-
aging this complex and timely study addressing the mutations
which drive this aggressive disease.
Although the ﬁndings from Li’s study are important to the
liver cancer ﬁeld and to the cancer NGS efforts as a whole, an
additional factor that must be considered in such studies is
patient diversity. For HCC in particular, one must consider that
HCC is a more aggressive disease in males vs. females, has diverse
racial/ethnic incidence rates with signiﬁcant bearing in Asians
and has several underlying risk factors including viral hepatitis
B and C, alcoholic disease and obesity. While the authors haveJournal of Hepatology 2012performed some initial analyses of these potential confounding
factors, well-deﬁned studies constructed with homogeneous
populations must be developed to address their impact on tumor
mutations (Fig. 1). Follow-up studies are also necessary to deter-
mine the functional consequence of these mutations.
Our ability to identify the mutations which drive tumorigen-
esis and progression has recently been expanded by the growing
ﬁeld of high-throughput sequencing. While recent endeavors,
such as those described in Li et al., have shown the power of
NGS technology to accelerate our understanding of cancer on
the genomic scale, we are only at the tip of the iceberg in terms
of our capacity to interpret the extensive resulting data. As ARID2
is a member of the chromatin remodeling complex, it is impor-
tant to note that NGS technology, via whole-genome bisulfate
sequencing methods, is extremely useful in deﬁning the epige-
netic alterations, such as DNA methylation and histone modiﬁca-
tions, that occur in cancer [9]. Ever-improving NGS-based
protocols are being employed to catalog the dynamics of the epi-
genome and its impact on cancer initiation and progression. In
the coming years, NGS and large-scale cancer genome studies
such as those launched by the International Cancer Genome Con-
sortium [10], along with novel technologies and informatics will
undoubtedly allow us to better translate research ﬁndings as clin-
ical tools to beneﬁt cancer patients.Conﬂict of interest
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